Type 2 Diabetes

Clinical Trial Finder

Many patients with type 2 diabetes are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

A Study to Investigate How Common Pancreatic Exocrine Insufficiency (PEI) is in Patients With Type 2 Diabetes and Also to Investigate the Uptake of a Single Dose of EPANOVA® or OMACOR® in Patients With Different Degrees of PEI

Conditions:   Diabetes Mellitus, Type 2;   Exocrine Pancreatic Insufficiency
Interventions:   Drug: Epanova® (omega-3 carboxylic acids);   Drug: Omacor® (omega-3-acid ethyl esters)
Sponsor:   AstraZeneca
Not yet recruiting - verified February 2015

The Effect of LINAGLIPTIN on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects

Condition:   Type 2 Diabetes
Interventions:   Drug: Linagliptin;   Drug: Placebo
Sponsors:   Kaleida Health;   University at Buffalo
Recruiting - verified February 2015

Fatty Acid Regulation of Platelet Function in Diabetes

Conditions:   Thrombosis;   Type 2 Diabetes Mellitus
Intervention:   Other: omega-3 and -6 fatty acids and their 12-LOX oxylipins
Sponsors:   University of Michigan;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 2015

Evaluation of an mHealth Behavioural Intervention for the Self-Management for Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Intervention:   Behavioral: Mobile application for diabetes self-management
Sponsors:   University Health Network, Toronto;   Mount Sinai Hospital, New York;   University of Toronto;   Canadian Institutes of Health Research  (CIHR)
Not yet recruiting - verified February 2015

A Clinical Trial to Investigate Safety/Tolerability and Pharmacokinetics of DA-1229_01(Evogliptin/Metformin XR 2.5/500 mg x 2 Tablets) Compared to Co-administration of Evogliptin 5 mg and Metformin XR 1000 mg in Healthy Male Volunteers

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: DA-1229_01;   Drug: E+M
Sponsor:   Dong-A ST Co., Ltd.
Not yet recruiting - verified February 2015

Role of Endoplasmic Reticulum Stress in the Pathophysiology of Type 2 Diabetes

Conditions:   Diabetes Mellitus, Type 2;   Endoplasmic Reticulum Stress
Intervention:   Other: No intervention
Sponsor:   Assistance Publique - Hôpitaux de Paris
Recruiting - verified February 2015

A Phase I Study to Assess the Pharmacodynamics of Oral AR-C165395XX in Subjects With Type 2 Diabetes Mellitus (T2DM)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: AR-C165395XX;   Other: Placebo
Sponsor:   AstraZeneca
Not yet recruiting - verified February 2015

A Phase 2a Pharmacodynamic Study of TAK-448 in Participants With Hypogonadotropic Hypogonadism

Condition:   Hypogonadotropic Hypogonadism
Intervention:   Drug: TAK-448
Sponsor:   Takeda
Not yet recruiting - verified February 2015

The PK/PD, Efficacy, Safety and Tolerability Study of SHR3824 in Combination With Metformin in Type 2 Diabetes Mellitus Patients

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: SHR3824;   Drug: Placebo;   Drug: Metformin
Sponsor:   Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting - verified February 2015

Shared Decision Making With Pharmaceutical Care

Condition:   Diabetes
Interventions:   Other: Diabetes Issue Cards Decision Aids;   Other: Usual Pharmaceutical Care
Sponsor:   Mayo Clinic
Recruiting - verified February 2015

The PK/PD, Efficacy, Safety and Tolerability Study of SHR3824 in Type 2 Diabetes Mellitus Patients

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: SHR3824;   Drug: Placebo
Sponsor:   Jiangsu HengRui Medicine Co., Ltd.
Recruiting - verified February 2015

Implementation of Foot Thermometry and SMS to Prevent Diabetic Foot Ulcer

Condition:   Diabetic Foot
Intervention:   Behavioral: SMS
Sponsors:   Universidad Peruana Cayetano Heredia;   Johns Hopkins University
Not yet recruiting - verified February 2015

Monitoring Obese Patients : Impact on the Frequency of Monitoring Weight

Conditions:   Obesity;   Morbid Obesity;   Quality of Life
Intervention:   Other: closer monitoring
Sponsors:   University Hospital, Limoges;   Centre de l'obésité Bernard Descottes
Not yet recruiting - verified February 2015

A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease

Conditions:   Type 2 Diabetes;   Chronic Kidney Disease
Interventions:   Drug: ASP8232;   Drug: Placebo
Sponsor:   Astellas Pharma Europe B.V.
Recruiting - verified February 2015

Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?

Condition:   Physical Activity
Interventions:   Drug: Dapagliflozin;   Drug: Placebo
Sponsors:   Christopher Bell;   AstraZeneca
Not yet recruiting - verified February 2015

Lidocaine + Clonidine for Intraoral Anesthesia in Patients With Diabetes Mellitus Type 2

Conditions:   Diabetes Mellitus;   Local Anesthesia
Interventions:   Procedure: L+C maxillary anesthesia;   Procedure: L+C mandibular anesthesia;   Procedure: L+E maxillary anesthesia;   Procedure: L+E mandibular anesthesia
Sponsor:   University of Belgrade
Enrolling by invitation - verified February 2015

Length of Effect of Extended Release Aspirin on Platelets in Patients With Diabetes and Heart Disease

Condition:   Cardiovascular Disease
Interventions:   Drug: Aspirin;   Drug: Durlaza™
Sponsor:   New Haven Pharmaceuticals, Inc.
Recruiting - verified February 2015

Sophia Step Study - a Behaviour Change Program on Physical Activity in Persons With Pre- and Type 2 Diabetes

Conditions:   Type 2 Diabetes;   Prediabetes
Interventions:   Behavioral: Pedometer intervention;   Behavioral: Group meetings;   Behavioral: Individual consultations
Sponsors:   Sophiahemmet University;   Karolinska Institutet;   Örebro University, Sweden
Recruiting - verified February 2015

Pharmacoepigenetics of Bipolar Disorder Treatment

Conditions:   Antipsychotic Agents;   Bipolar Disorder
Intervention:  
Sponsor:   Wayne State University
Not yet recruiting - verified February 2015

Safety, Tolerability and PK of Imeglimin in Japanese Volunteers

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Imeglimin;   Drug: Placebo
Sponsor:   Poxel SA
Recruiting - verified February 2015

Effects of Barley on Glucose Control

Condition:   Healthy
Interventions:   Dietary Supplement: 0g of barley  β-glucan;   Dietary Supplement: 2g of barley  β-glucan;   Dietary Supplement: 4g of barley  β-glucan;   Dietary Supplement: 8g of barley  β-glucan
Sponsors:   St. Boniface General Hospital Research Centre;   Agriculture and Agri-Food Canada
Not yet recruiting - verified February 2015

SIT LESS 2: Effect of Sitting Less on Glucose Regulation in People With Diabetes Mellitus Type 2

Condition:   Type 2 Diabetes
Intervention:   Behavioral: Physical activity intervention
Sponsors:   Maastricht University Medical Center;   Novo Nordisk A/S
Recruiting - verified February 2015

A Study to Evaluate the Safety and Efficacy of RM-131 Administered to Patients With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis

Conditions:   Diabetes Mellitus;   Diabetes Mellitus Complications;   Gastroparesis
Interventions:   Drug: RM-131;   Drug: Placebo
Sponsor:   Rhythm Pharmaceuticals, Inc.
Recruiting - verified February 2015

Racial Differences in Vagal Control of Glucose Homeostasis

Condition:   Obesity
Interventions:   Drug: Galantamine;   Drug: Placebo
Sponsors:   Vanderbilt University;   Doris Duke Charitable Foundation
Not yet recruiting - verified February 2015

Risk of Nocturnal Hypoglycemia and Arrhythmias With Sitagliptin Versus Glimepiride in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus Type 2
Interventions:   Drug: Sitagliptin;   Drug: Glimepiride;   Drug: Sitagliptin-Placebo;   Drug: Glimepiride-Placebo
Sponsor:   GWT-TUD GmbH
Not yet recruiting - verified February 2015

Glucose Variability Pilot Study for the Abbott Sensor Based Glucose Monitoring System-Professional

Condition:   Type 2 Diabetes Mellitus
Intervention:   Device: Abbott Sensor Based Glucose Monitoring System-Professional
Sponsor:   Abbott Diabetes Care
Recruiting - verified February 2015

Mechanistic Study of the Systolic Blood Pressure Lowering Effect of Dapagliflozin in Type 2 Diabetes

Condition:   Diabetes Mellitus Type 2
Interventions:   Drug: dapagliflozin;   Drug: glimpiride
Sponsor:   Gulf Regional Research & Educational Services, LLC
Recruiting - verified February 2015

An Efficacy and Safety Study of Beloranib in Obese Subjects With Type 2 Diabetes Mellitus

Conditions:   Obesity;   Type 2 Diabetes
Interventions:   Drug: ZGN-440 for Injectable Suspension;   Drug: ZGN-440 Placebo for Injectable Suspension
Sponsor:   Zafgen, Inc.
Recruiting - verified February 2015

Intra-individual Variability and Circadian Rhythm of VEGF Levels and Interaction With Biomarkers

Condition:   Diabetic Macular Edema
Intervention:   Other: Frequent blood and urine sampling and blood pressure measurement
Sponsors:   GWT-TUD GmbH;   Novartis
Recruiting - verified February 2015

Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine U300 HOE901;   Drug: Insulin glargine HOE901
Sponsor:   Sanofi
Recruiting - verified February 2015

Efficacy of Sitagliptin and Glibenclamide on the Glucose Glucose Variability in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431-355)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin;   Drug: Glibenclamide
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified February 2015

Study of Gelesis100 on Body Weight in Overweight and Obese Subjects With and Without Type 2 Diabetes

Conditions:   Overweight;   Obesity
Interventions:   Device: Gelesis100;   Device: placebo
Sponsor:   Gelesis, Inc.
Recruiting - verified January 2015

A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: LY2963016;   Drug: LANTUS®;   Drug: Oral Antihyperglycemic Medication
Sponsors:   Eli Lilly and Company;   Boehringer Ingelheim
Recruiting - verified February 2015

Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: SAR342434;   Drug: insulin lispro;   Drug: insulin glargine HOE901
Sponsor:   Sanofi
Recruiting - verified February 2015

Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Bydureon;   Drug: Placebo
Sponsor:   AstraZeneca
Recruiting - verified February 2015

Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone

Condition:   Type 2 Diabetes
Interventions:   Drug: Saxagliptin;   Drug: Dapagliflozin;   Drug: Sitagliptin;   Drug: Placebo matching with Saxagliptin;   Drug: Placebo matching with Dapagliflozin;   Drug: Placebo matching with Sitagliptin
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Recruiting - verified February 2015

The Effect of Plant Sterols on the Blood Lipid Profile of Subjects With and at High Risk of Type 2 Diabetes Mellitus

Conditions:   Vascular Diseases;   Hypercholesterolemia;   Diabetes Mellitus
Interventions:   Dietary Supplement: Plant sterols;   Dietary Supplement: Placebo product
Sponsors:   Unilever R&D;   CSIRO
Recruiting - verified September 2014

A German Study Evaluating the Efficacy and the Benefit of Integrated Personalized Diabetes Management (PDM) for Type 2 Diabetes Patients.

Condition:   Diabetes
Interventions:   Device: Accu-Chek Smart Pix Software;   Device: Accu-Chek Smart Pix readout Device
Sponsors:   Hoffmann-La Roche;   Roche Diagnostics Deutschland GmbH
Recruiting - verified October 2014

Linagliptin as Add on to Basal Insulin in the Elderly

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: placebo;   Drug: linagliptin
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified February 2015

DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Setting in Japan

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsors:   AstraZeneca;   Ono Pharmaceutical Co. Ltd
Recruiting - verified February 2015

Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus

Condition:   Diabetes Mellitus
Interventions:   Drug: Exenatide;   Drug: Exenatide matching placebo
Sponsor:   AstraZeneca
Recruiting - verified February 2015

Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin;   Drug: Sitagliptin;   Drug: Placebo to Ertugliflozin;   Drug: Placebo to Sitagliptin;   Drug: Glimepiride
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Recruiting - verified February 2015

Phase 3 28 Week Study and 24 Week Extension to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo

Condition:   Diabetes Mellitus
Interventions:   Drug: Exantide with Dapagliflozin;   Drug: Exentide;   Drug: Dapagliflozin
Sponsor:   AstraZeneca
Recruiting - verified February 2015

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease

Conditions:   Chronic Kidney Disease (CKD);   Type 2 Diabetes Mellitus (T2DM);   Healthy Subjects;   Pharmacokinetics of ASP8232;   Pharmacodynamics of ASP8232
Interventions:   Drug: ASP8232;   Drug: Placebo
Sponsor:   Astellas Pharma Europe B.V.
Completed - verified February 2015

A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis

Condition:   Gastroparesis
Interventions:   Drug: Placebo;   Drug: Camicinal
Sponsor:   GlaxoSmithKline
Recruiting - verified December 2014

A Study of Once-Daily RO6811135 in Patients With Type 2 Diabetes Inadequately Controlled With Metformin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Liraglutide;   Drug: Placebo QD;   Drug: RO6811135
Sponsor:   Hoffmann-La Roche
Recruiting - verified February 2015

A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered With Metformin to Type 2 Diabetes Patients

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GSK2330672;   Drug: Placebo;   Drug: Sitagliptin;   Drug: Metformin
Sponsor:   GlaxoSmithKline
Completed - verified February 2015

Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: LIXISENATIDE AVE0010;   Drug: Sitagliptin;   Drug: Insulin glargine HOE901
Sponsor:   Sanofi
Recruiting - verified February 2015

Hypertriglyceridaemia - Cause and Effects

Condition:   Hypertriglyceridaemia
Intervention:  
Sponsor:   Central Manchester University Hospitals NHS Foundation Trust
Recruiting - verified February 2015

24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension

Conditions:   Diabetes Mellitus, Type 2;   Hypertension
Interventions:   Drug: Empagliflizon low dose;   Drug: placebo;   Drug: Empagliflizon high dose
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified February 2015

Paraoxonase and HDL Qualities in Glycaemia and Inflammation

Conditions:   Diabetes.;   Bariatric Surgery.
Intervention:  
Sponsors:   Central Manchester University Hospitals NHS Foundation Trust;   British Heart Foundation;   Juvenile Diabetes Research Foundation
Recruiting - verified February 2015

A Study to Investigate in Healthy Volunteers (Part 1) and in Patients With Type 2 Diabetes Mellitus (Part 2) the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of RO6799477

Condition:   Healthy Volunteer, Type 2 Diabetes
Interventions:   Drug: Placebo;   Drug: RO6799477
Sponsor:   Hoffmann-La Roche
Completed - verified February 2015

A Prospective, Multicenter, Randomized, Open-label Study of 12 Week Duration to Evaluate the Effect of VILDagliptin Added to Insulin on Glycaemic Control in haemoDIALyzed Patients With Type 2 Diabetes: Probe Analysis of CGM

Condition:   Haemodialyzed, Type 2 Diabetes
Interventions:   Drug: Vildagliptin (Galvus);   Drug: Insulin
Sponsors:   University Hospital, Strasbourg, France;   Novartis
Recruiting - verified June 2014

A Study Evaluating the Efficacy and the Benefit of Integrated Personalized Diabetes Management (PDM) for Diabetic Patients.

Condition:   Diabetes Mellitus Type 2
Interventions:   Device: Accu-Chek Smart Pix Software;   Device: Accu-Chek Smart Pix readout Device
Sponsors:   Hoffmann-La Roche;   Roche Diagnostics Deutschland GmbH
Recruiting - verified March 2014

Pyridorin in Diabetic Nephropathy

Conditions:   Diabetic Nephropathy;   Diabetic Kidney Disease
Interventions:   Drug: Pyridorin;   Drug: Placebo
Sponsors:   NephroGenex, Inc.;   Collaborative Study Group (CSG);   Medpace, Inc.
Recruiting - verified February 2015

A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified January 2015

Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: empagliflozin medium dose;   Drug: empagliflozin high dose;   Drug: empagliflozin low dose
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified February 2015

A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: LY2944876;   Drug: Exenatide extended-release;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Active, not recruiting - verified February 2015

Low Level Laser Treatment (LLLT) and Lorcaserin for Weight Management

Conditions:   Overweight;   Obese
Interventions:   Device: LLLT;   Drug: Lorcaserin
Sponsor:   Mayo Clinic
Active, not recruiting - verified February 2015

Ertugliflozin and Sitagliptin Co-administration Factorial Study (MK-8835-005)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Matching Placebo to Ertugliflozin 5 mg;   Drug: Matching Placebo to Ertugliflozin 10 mg;   Drug: Matching Placebo to sitagliptin 100 mg;   Drug: Ertugliflozin 5 mg;   Drug: Ertugliflozin 10 mg;   Drug: Sitagliptin 100 mg;   Drug: Metformin >= 1500 mg/day;   Biological: Insulin Glargine Rescue Medication;   Drug: Glimepiride Rescue Medication
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Recruiting - verified February 2015

Phase III Insulin Add-On Asia Regional Program - ST

Condition:   Diabetes
Interventions:   Drug: Dapagliflozin;   Drug: Dapagliflozin Placebo
Sponsor:   Bristol-Myers Squibb
Recruiting - verified February 2015

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Insulin glargine/lixisenatide HOE901/AVE0010;   Drug: Insulin glargine HOE901;   Drug: Metformin
Sponsor:   Sanofi
Recruiting - verified February 2015

Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM

Condition:   Type 2 Diabetes
Interventions:   Drug: Insulin glargine/lixisenatide HOE901/AVE0010;   Drug: Insulin glargine HOE901;   Drug: Lixisenatide AVE0010;   Drug: Metformin
Sponsor:   Sanofi
Recruiting - verified February 2015

An Exploratory Clinical Trial to Generate Whole Blood Samples for Analysing Genetic Polymorphisms

Conditions:   Prediabetes;   Diabetes Type 1;   Diabetes Type 2
Intervention:  
Sponsor:   Profil Institut für Stoffwechselforschung GmbH
Not yet recruiting - verified February 2015

Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 Diabetes

Condition:   Patient With Type 2 Diabetes Treated With Insulin Using a Baseline/Bolus Strategy
Interventions:   Drug: LEVEMIR;   Drug: APIDRA
Sponsor:   Centre Hospitalier Universitaire Dijon
Recruiting - verified February 2012

Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin (5 mg);   Drug: Ertugliflozin (15 mg);   Drug: Placebo;   Drug: Metformin;   Drug: Sitagliptin;   Drug: Glimepiride;   Biological: Insulin
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Recruiting - verified February 2015

A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec;   Drug: insulin glargine
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified February 2015

A Study of the Safety and Effectiveness of LY3053102 in Participants With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: LY3053102;   Drug: Exenatide extended release;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Terminated - verified February 2015

Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Canagliflozin, 100 mg;   Drug: Canagliflozin, 300 mg;   Drug: Placebo
Sponsor:   Janssen Research & Development, LLC
Recruiting - verified February 2015

Effectiveness Study of Interactive Web Application for Problem Solving in Diabetes Management

Condition:   Diabetes Mellitus
Interventions:   Behavioral: Early Mobile Diabetes Detective (MoDD);   Behavioral: Late Mobile Diabetes Detective (MoDD)
Sponsors:   Columbia University;   Clinical Directors Network;   Georgia Institute of Technology;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified February 2015

Prevention of Microvascular Complications in Overweight Diabetics With Surgery or Best Medicine

Condition:   Diabetic Kidney Disease
Interventions:   Procedure: Optimal medical treatment and surgery;   Procedure: Optimal medical treatment
Sponsors:   Karolinska Institutet;   St. Claraspital AG
Recruiting - verified February 2015

MK-8835/PF-04971729 vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin 5 mg;   Drug: Ertugliflozin 10 mg;   Drug: Glimerpiride;   Drug: Placebo to Ertugliflozin;   Drug: Placebo to Glimepiride;   Drug: Metformin;   Drug: Sitagliptin
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified February 2015

A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Ticagrelor 90 mg;   Drug: Ticagrelor placebo
Sponsor:   AstraZeneca
Recruiting - verified February 2015

Pre-meal Protein Drink Improve Glycemic Regulation

Condition:   Type 2 Diabetes Mellitus
Interventions:   Dietary Supplement: Pre-meal protein drink;   Other: Water drink
Sponsors:   Lund University;   Landstinget i Kalmar Län
Enrolling by invitation - verified February 2015

Cardiovascular Outcomes Following Treatment With Ertugliflozin in Participants With Type 2 Diabetes Mellitus and Established Vascular Disease (MK-8835-004)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin;   Drug: Placebo
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Recruiting - verified February 2015

A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin;   Drug: Placebo
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Recruiting - verified February 2015

Identification of Biomarkers for Obstructive Sleep Apnoea Syndrome

Condition:   Obstructive Sleep Apnoea Syndrome
Intervention:  
Sponsors:   Universidade Nova de Lisboa;   Centro de Estudos de Doenças Crónicas;   NOVA Medical School;   Centro Hospitalar Lisboa Norte;   Instituto Nacional de Saúde Dr. Ricardo Jorge;   Biotempo;   Fundação para a Ciência e a Tecnologia
Completed - verified February 2015

A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus

Conditions:   Diabetes Mellitus, Type 2;   Albuminuria
Interventions:   Drug: Placebo;   Drug: Canagliflozin, 100 mg;   Drug: Canagliflozin, 300 mg
Sponsor:   Janssen Research & Development, LLC
Recruiting - verified February 2015

Study to Assess the Dietary Carbohydrate Content of Indian Diabetics With Special Therapeutic View on Effectiveness of Acarbose and Metformin Monotherapy

Condition:   Diabetes Mellitus
Interventions:   Drug: Bay G5421 Glucobay;   Drug: Metformin
Sponsor:   Bayer
Not yet recruiting - verified February 2015

Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: lixisenatide AVE0010;   Drug: biguanide;   Drug: TZD;   Drug: alpha-GI;   Drug: glinide
Sponsor:   Sanofi
Active, not recruiting - verified February 2015

Metabolic Clock Genes During Fasting and After Food Intake in Type 2 Diabetics

Condition:   Type 2 Diabetes
Interventions:   Other: Fasting No Breakfast (NoB);   Other: Yes Breakfast  (YesB)
Sponsor:   Tel Aviv University
Recruiting - verified February 2015

Mechanisms of Diabetes Control After Weight Loss Surgery, Sub-study #1

Conditions:   Gastric Bypass Surgery;   Gastric Banding;   Type 2 Diabetes
Intervention:  
Sponsors:   St. Luke's-Roosevelt Hospital Center;   National Institutes of Health (NIH)
Recruiting - verified February 2015

GLucobay M - Evaluation Of Safety and Effectiveness in Type 2 Diabetes Not Well Controlled on Monotherapy in Real Life Practice

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Acarbose/Metformin (Glucobay M, BAY81-9783)
Sponsor:   Bayer
Not yet recruiting - verified February 2015

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Linagliptin
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified February 2015

A Study Comparing LY2605541 With Insulin Glargine as Basal Insulin Treatment

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: LY2605541;   Drug: Insulin Glargine
Sponsor:   Eli Lilly and Company
Active, not recruiting - verified February 2015

Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: exenatide
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified February 2015

Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Metformin XR;   Drug: Metformin IR;   Drug: Placebo matching with Metformin XR;   Drug: Placebo matching with Metformin IR
Sponsor:   Bristol-Myers Squibb
Recruiting - verified October 2014

Markers of Bone Status in Diabetes Mellitus (Type 1 and Type 2)

Conditions:   Diabetes Mellitus;   Osteoporosis;   Osteopenia
Intervention:  
Sponsor:   Jakob Starup Linde
Active, not recruiting - verified February 2015

Fatty Liver Study in Patients With Type II Diabetes

Conditions:   Type II Diabetes;   Nonalcoholic Fatty Liver
Interventions:   Drug: DPP4 inhibitor;   Drug: Pioglitazone;   Drug: Lantus insulin
Sponsor:   The University of Texas, Galveston
Recruiting - verified February 2015

A Study of the Safety and Efficacy of MK-3102 in ≥18 and <45 Year-Old Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028)

Condition:   Diabetes Mellitus
Interventions:   Drug: MK-3102;   Drug: Placebo to MK-3102;   Drug: Metformin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified February 2015

Epigenetic and Developmental Effects of In Utero Exposure to Environmental Toxicants

Conditions:   Full Term Infants;   Environmental Exposures;   Adiposity
Intervention:  
Sponsors:   Montefiore Medical Center;   American Diabetes Association
Recruiting - verified February 2015

Study on Improvement of Blood Glucose Control in Patients With Diabetes Type 2 Using SMBG

Condition:   Diabetes
Intervention:   Device: ;Accu-Chek Compact Plus LCM bulk Japan
Sponsor:   Hoffmann-La Roche
Completed - verified February 2013

Extension Study for 2993-112

Condition:   Type 2 Diabetes Mellitus
Intervention:   Drug: AC2993
Sponsor:   AstraZeneca
Completed - verified January 2015

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: BI 10773;   Drug: BI 10773 Placebo;   Drug: BI 10773 / BI 1356;   Drug: BI 10773;   Drug: BI 10773 / BI 1356;   Drug: BI 10773 / BI 1356 Placebo;   Drug: BI 10773;   Drug: BI 10773;   Drug: BI 10773;   Drug: BI 10773 / BI 1356 Placebo;   Drug: BI 10773 Placebo;   Drug: BI 10773 / BI 1356 Placebo;   Drug: BI 10773;   Drug: BI 10773 / BI 1356 Placebo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting - verified February 2015

A Study of the Safety and Efficacy of MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-289)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin + Metformin XR FDC;   Drug: Placebo to Sitagliptin + Metformin XR;   Drug: Metformin XR;   Drug: Placebo to metformin XR;   Drug: Insulin glargine;   Biological: Background insulin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified February 2015

A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of MK-3102 to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: MK-3102;   Drug: Matching placebo to MK-3102;   Drug: Glimepiride;   Drug: Matching placebo to glimepiride;   Drug: Insulin glargine;   Drug: Metformin
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified February 2015

Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: BMS-813160;   Drug: Placebo matching with BMS-813160
Sponsor:   Bristol-Myers Squibb
Recruiting - verified August 2014

Better Diabetes Control, Quality - Educate to Achieve Compliance

Condition:   Diabetes Type 2
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified February 2015

Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Linagliptin;   Drug: Empagliflozin + Linagliptin;   Drug: Empagliflozin + Linagliptin;   Drug: Empagliflozin + Linagliptin;   Drug: Empaglifozin placebo + Linagliptin placebo;   Drug: Empagliflozin + Linagliptin
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting - verified February 2015

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Condition:   Cardiovascular Disease, Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: aleglitazar
Sponsor:   Hoffmann-La Roche
Completed - verified February 2015

A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: aleglitazar
Sponsor:   Hoffmann-La Roche
Completed - verified February 2015

Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Dapagliflozin;   Drug: Placebo matching with Dapagliflozin;   Drug: Saxagliptin;   Drug: Metformin immediate release (IR)
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Active, not recruiting - verified October 2014

Resistance Training and Testosterone After Spinal Cord Injury

Condition:   Spinal Cord Injury
Interventions:   Procedure: Resistance Training and Testosterone Patches;   Drug: Testosterone Patches
Sponsors:   Department of Veterans Affairs;   Virginia Commonwealth University
Recruiting - verified February 2015

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

Conditions:   Type 2 Diabetes;   Chronic Kidney Disease
Interventions:   Drug: Dulaglutide;   Drug: Insulin glargine;   Drug: Insulin lispro
Sponsor:   Eli Lilly and Company
Recruiting - verified February 2015

Evaluation of CONTOUR® USB BGMS on Glycaemic Control in Insulin-treated Diabetic Patients

Condition:   Diabetes Mellitus Type 2
Intervention:  
Sponsors:   GWT-TUD GmbH;   Bayer
Recruiting - verified February 2015

Diet and Exercise in Type 2 Diabetes - a Randomized Controlled Trial

Condition:   Diabetes Mellitus, Type 2
Interventions:   Behavioral: Modified paleolithic diet and exercise under observation;   Behavioral: Modified paleolithic diet and general advice on exercise
Sponsor:   Umeå University
Completed - verified February 2015

Study of RO6807952 in Patients With Diabetes Mellitus Type 2

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RO6807952;   Drug: RO6807952;   Drug: liraglutide
Sponsor:   Hoffmann-La Roche
Terminated - verified February 2015

Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: liraglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Completed - verified February 2015

Safety and Efficacy of YH14617 in Diabetes Mellitus

Condition:   Diabetes Mellitus
Interventions:   Drug: YH14617;   Drug: YH14617;   Drug: YH14617;   Drug: Placebo
Sponsors:   Yuhan Corporation;   Peptron, Inc.
Completed - verified February 2015

Life-long Tele-monitoring of Patients With Type 2 Diabetes Mellitus in Central Greece

Condition:   Diabetes Mellitus, Type 2
Intervention:   Procedure: Telemonitoring of patients with diabetes type 2
Sponsors:   Regional Health Authority of Sterea & Thessaly;   Ministry for Health and Social Solidarity, Greece;   Municipality of Trikala, Greece;   e-trikala SA, Greece;   Cities Net SA, Greece;   Biomedical Research & Technology (BIOMED, Larissa, Greece;   Institute of Communications and Computer Systems, Athens, Greece;   Alexander Technological Educational Institute, Thessaloniki, Greece;   University of Macedonia, Thessaloniki, Greece;   University of Thessaly
Completed - verified February 2015

A Study of the Safety and Efficacy of MK-0431A in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-170)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Metformin;   Drug: Sitagliptin + Metformin FDC;   Drug: Placebo to Metformin;   Drug: Placebo to Sitagliptin + Metformin FDC;   Biological: Insulin;   Biological: Insulin glargine
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified February 2015

Matrix Metalloproteinases in Atherosclerosis of Chronic Kidney Disease

Condition:   Diabetic Nephropathy
Intervention:  
Sponsors:   Aristotle University Of Thessaloniki;   AHEPA University Hospital
Recruiting - verified February 2015

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo matching with Saxagliptin;   Drug: Metformin IR;   Drug: Metformin XR;   Drug: Saxagliptin;   Drug: Saxagliptin
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Recruiting - verified April 2014

An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsor:   Eli Lilly and Company
Active, not recruiting - verified February 2015

Effects of Glucagon Like Peptide-1(GLP-1) and Liraglutide on Brain Satiety and Reward Circuits and Feeding Behavior in Diabetes

Conditions:   Obesity;   Type 2 Diabetes
Interventions:   Drug: Liraglutide treatment 12 weeks;   Drug: insulin glargine treatment;   Drug: GLP-1 receptor antagonist
Sponsor:   VU University Medical Center
Completed - verified February 2015

CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: linagliptin;   Drug: glimepiride;   Drug: linagliptin placebo;   Drug: glimepride placebo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting - verified February 2015

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Saxagliptin;   Drug: Placebo (Saxagliptin);   Drug: Metformin IR;   Drug: Placebo (Metformin);   Drug: Metformin (Active Rescue)
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Recruiting - verified April 2014

BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: BI 10773 low dose;   Drug: Placebo BI 10773 high dose;   Drug: BI 10773 high dose;   Drug: Placebo BI 10773 low dose;   Drug: Placebo BI 10773 low dose;   Drug: Placebo BI 10773 high dose
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting - verified February 2015

Evaluation of Oral Alpha-Cyclodextrin for Decreasing Serum Cholesterol

Condition:   Cardiovascular Disease
Interventions:   Other: Placebo;   Drug: Alpha-CD
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified November 2014

A Trial Investigating NN1218 in Subjects With Type 1 and Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 1;   Diabetes Mellitus, Type 2
Interventions:   Drug: Faster-acting insulin aspart;   Drug: insulin aspart;   Drug: Faster-acting insulin aspart;   Drug: Faster-acting insulin aspart;   Drug: Faster-acting insulin aspart
Sponsor:   Novo Nordisk A/S
Completed - verified February 2015

A Comparison Study of Prototype Continuous Glucose Sensors in the Intradermal and Subcutaneous Spaces

Condition:   Diabetes
Interventions:   Device: BD Continuous glucose monitor (BD CGM);   Device: YSI Glucose Analyzer;   Device: Medtronic Guardian CGM
Sponsor:   Becton, Dickinson and Company
Completed - verified February 2015

Observational Study of Somatropin Treatment in Children

Conditions:   Dwarfism, Growth Hormone Deficiency;   Turner Syndrome;   Infant, Small for Gestational Age;   SHOX Protein, Human
Intervention:   Drug: Somatropin (rDNA origin)
Sponsor:   Eli Lilly and Company
Active, not recruiting - verified February 2015

A Study of RO5095932 in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: RO5095932;   Drug: RO5095932;   Drug: metformin;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified February 2015

An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Intervention:   Drug: exenatide
Sponsors:   AstraZeneca;   Eli Lilly and Company
Completed - verified January 2015

Natural History of Autoimmune Diabetes and Its Complications

Conditions:   Type 1 Diabetes;   Type 2 Diabetes;   Immunologically Mediated Type 1 Diabetes;   Anti Beta-Cell Autoantibodies;   Autoimmunity
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified February 2015

Genetics of Type 2 Diabetes in West Africans

Conditions:   Hypertension;   Diabetes
Intervention:  
Sponsor:   National Human Genome Research Institute (NHGRI)
Recruiting - verified November 2014

Sitagliptin Cardiovascular Outcome Study (MK-0431-082)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin phosphate;   Drug: Placebo
Sponsors:   Merck Sharp & Dohme Corp.;   Duke Clinical Research Institute, Oxford Diabetes Trials Unit
Active, not recruiting - verified February 2015

A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: placebo;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified February 2015

A Multiple Ascending Dose Study of RO4998452 in Patients With Type 2 Diabetes Mellitus.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: RO4998452;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified February 2015

Post Marketing Surveillance Study of Byetta ™ (Exenatide) Use Among Filipino Patients

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsors:   AstraZeneca;   Eli Lilly and Company
Completed - verified January 2015

A Study to Examine Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: exenatide once weekly;   Drug: placebo
Sponsors:   AstraZeneca;   Eli Lilly and Company
Completed - verified January 2015

Exenatide Pregnancy Registry - Type 2 Diabetes in Pregnancy

Conditions:   Birth Defects;   Type 2 Diabetes;   Preterm Birth
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified February 2015

A Study by Scintigraphy to Evaluate the Effect of Exenatide on Gastric Emptying in Subjects With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: exenatide and placebo;   Drug: Exenatide and placebo;   Drug: Exenatide and placebo
Sponsors:   AstraZeneca;   Eli Lilly and Company
Completed - verified January 2015

A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: taspoglutide;   Drug: taspoglutide;   Drug: taspoglutide;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified February 2015

A Study of Aleglitazar in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Actos;   Drug: Placebo;   Drug: aleglitazar
Sponsor:   Hoffmann-La Roche
Completed - verified February 2015

A Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 In Japanese Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: exenatide (LY2148568);   Drug: exenatide (LY2148568);   Drug: exenatide (LY2148568);   Drug: Placebo
Sponsors:   AstraZeneca;   Eli Lilly and Company
Completed - verified January 2015

Safety and Efficacy of Exenatide as Monotherapy

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: exenatide;   Drug: exenatide;   Drug: placebo
Sponsors:   AstraZeneca;   Eli Lilly and Company
Completed - verified January 2015

Comparison of Exenatide Taken Before Lunch and Dinner With Before Breakfast and Dinner in Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: exenatide;   Drug: exenatide
Sponsors:   AstraZeneca;   Eli Lilly and Company
Completed - verified January 2015

Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and Metformin

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: exenatide;   Drug: Placebo
Sponsors:   AstraZeneca;   Eli Lilly and Company
Completed - verified January 2015

A Research Study to Evaluate the Renal (Kidney) Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes (0954-147)(COMPLETED)

Conditions:   Type 2 Diabetes;   Nephropathy
Interventions:   Drug: MK0954, losartan / Duration of Treatment: mean 3.4 years;   Drug: Placebo / Duration of Treatment: mean 3.4 years
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified February 2015

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Exenatide in Adolescent Subjects With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Exenatide - Exenatide - Placebo;   Drug: Exenatide - Placebo - Exenatide;   Drug: Placebo - Exenatide - Exenatide
Sponsors:   AstraZeneca;   Eli Lilly and Company
Completed - verified January 2015

Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: exenatide;   Drug: Placebo
Sponsors:   AstraZeneca;   Eli Lilly and Company
Completed - verified January 2015

Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: exenatide
Sponsor:   AstraZeneca
Completed - verified January 2015

Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: placebo;   Drug: placebo;   Drug: Exenatide LAR;   Drug: Exenatide LAR
Sponsors:   AstraZeneca;   Eli Lilly and Company
Completed - verified January 2015

Comparing Exenatide and Insulin Glargine in Type 2 Diabetes Patients for Whom Insulin is the Next Appropriate Therapy

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: exenatide/insulin glargine;   Drug: insulin glargine/exenatide
Sponsors:   AstraZeneca;   Eli Lilly and Company
Completed - verified January 2015

Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: exenatide;   Drug: Placebo
Sponsors:   AstraZeneca;   Eli Lilly and Company
Completed - verified January 2015

Study of the Safety of Substituting Exenatide for Insulin in Patients Using Insulin and Oral Antidiabetic Agents

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: exenatide;   Drug: Insulin
Sponsors:   AstraZeneca;   Eli Lilly and Company
Completed - verified January 2015

Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo 0.04 mL twice daily;   Drug: Placebo 0.04 mL once daily;   Drug: Placebo 0.08 mL once daily;   Drug: B - Exenatide 10 mcg twice daily;   Drug: C - Exenatide 10 mcg once daily;   Drug: Exenatide 20 mcg once daily
Sponsors:   AstraZeneca;   Eli Lilly and Company
Completed - verified January 2015

Urinary Vitamin C Loss in Diabetic Subjects

Conditions:   Diabetes Type 1;   Diabetes Type 2;   Healthy Volunteers
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified April 2014

Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Non-Insulin-Dependent
Interventions:   Drug: Placebo 0.01 mL;   Drug: Placebo 0.02 mL;   Drug: Placebo 0.03 mL;   Drug: Placebo 0.04 mL;   Drug: AC2993 2.5 mcg;   Drug: AC2993 5.0 mcg;   Drug: AC2993 7.5 mcg;   Drug: AC2993 10.0 mcg
Sponsor:   AstraZeneca
Completed - verified January 2015

Evaluation of the Effect on Glucose Control and Safety of AC2993 in Patients With Type 2 Diabetes Treated With Metformin, Sulfonylurea, or Metformin and Sulfonylurea Combination

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: AC2993
Sponsors:   AstraZeneca;   Eli Lilly and Company
Completed - verified January 2015

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea

Condition:   Diabetes Mellitus, Non-Insulin-Dependent
Interventions:   Drug: AC2993;   Drug: AC2993;   Drug: Placebo;   Drug: Placebo
Sponsor:   AstraZeneca
Completed - verified January 2015

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: AC2993;   Drug: AC2993;   Drug: Placebo;   Drug: Placebo
Sponsor:   AstraZeneca
Completed - verified January 2015

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Non-Insulin-Dependent
Interventions:   Drug: AC2993;   Drug: AC2993;   Drug: Placebo;   Drug: Placebo
Sponsor:   AstraZeneca
Completed - verified January 2015

Get CardioSmart

You're Invited